Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cel-Sci Corp
(NY:
CVM
)
0.6110
-0.0050 (-0.81%)
Official Closing Price
Updated: 8:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cel-Sci Corp
< Previous
1
2
3
4
5
6
Next >
CMG Stock Alert: Chipotle Announces International Expansion Plan
July 18, 2023
Chipotle Mexican Grill (CMG) stock is in the news Tuesday after the restaurant chain announced plans for an international expansion.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
July 18, 2023
Via
Benzinga
Why Is CEL-SCI (CVM) Stock Down 23% Today?
July 18, 2023
CEL-SCI (CVM) stock is dropping on Tuesday after the biotechnology company announced details of a public share offering.
Via
InvestorPlace
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
July 18, 2023
Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
July 18, 2023
It's time to start off trading for Tuesday with a breakdown of the biggest pre-market stock movers worth watching this morning.
Via
InvestorPlace
CEL-SCI Announces Pricing of Public Offering
July 17, 2023
From
CEL-SCI Corporation
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
July 17, 2023
Via
Benzinga
CEL-SCI Announces Proposed Public Offering of Common Stock
July 17, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine’s Approval for Head & Neck Cancer
July 14, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer
July 11, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer—New Patent to Be Filed
June 22, 2023
From
CEL-SCI Corporation
Via
Business Wire
Why CEL-SCI Shares Are Shooting Higher Today
May 15, 2023
CEL-SCI Corporation (NYSE: CVM) announced that the latest results from its pivotal Phase 3 study of Multikine, a presurgical cancer immunotherapy, were presented at the European Society for...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 15, 2023
Via
Benzinga
Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI’s Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023
May 15, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
May 12, 2023
From
CEL-SCI Corporation
Via
Business Wire
Why BlackBerry Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
May 02, 2023
Gainers Leju Holdings Limited (NYSE: LEJU) gained 103.7% to $7.25 in pre-market trading after jumping around 97% on Monday .
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
May 02, 2023
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday!
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 01, 2023
Via
Benzinga
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock
April 27, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer
April 19, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI's Lead Head & Neck Cancer Candidate Shows 43% Survival Extension
March 08, 2023
Via
Benzinga
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
March 08, 2023
From
CEL-SCI Corporation
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
March 08, 2023
We're getting into the biggest pre-market stock movers traders will want to keep an eye on Wednesday with the latest news!
Via
InvestorPlace
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 03, 2023
Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland.
Via
Benzinga
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
March 03, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results
February 15, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tesla To $250? Here Are 10 Other Price Target Changes For Thursday
December 29, 2022
Morgan Stanley cut Tesla, Inc. (NASDAQ: TSLA) price target from $330 to $250. Morgan Stanley analyst Adam Jonas maintained an Overweight rating on the stock. Tesla shares rose 4.4% to $117.65 in...
Via
Benzinga
CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments
December 28, 2022
From
CEL-SCI Corporation
Via
Business Wire
10-Year Phase 3 Trial Shows CEL-SCI's Multikine immunotherapy Extends Lives In Head & Neck Cancer Patients
November 22, 2022
Via
Benzinga
CEL-SCI Corporation Issues Letter to Shareholders
November 22, 2022
From
CEL-SCI Corporation
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.